Tumor
Servier’s $1.8 Billion Acquisition Pays Off: FDA Approves First-In-Class Treatment for Two Types of Rare Brain Cancer
2024-08-07
The Maturation of Blood-Based Diagnostics to Nip Cancers in the Bud: An Interview with Dr. Jimmy Lin
2021-06-02
ASGCT21 Highlights: Present Trends and Future Directions of Gene and Cell Therapies in Immuno-Oncology
2021-05-14
A New Imaging Tool Predicts Response of Cancer Patients to Immune Checkpoint Inhibition Therapy
2020-08-30